Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
Corcept (CORT) Up More Than 50% in Past 3 Months: Here's Why
10:32am, Thursday, 31'st Dec 2020
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.
Corcept Therapeutics Appoints Gillian M. Cannon, PhD, to Board of Directors
05:00pm, Monday, 23'rd Nov 2020
MENLO PARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met
Pharma Stocks: Why Corcept Therapeutics Stock Is Soaring 24% Today
12:12pm, Thursday, 19'th Nov 2020
Corcept Therapeutics (CORT) is leading pharma stocks news on Thursday with approval from the U.S. Patent and Trademark Office's PTAB. The post Pharma Stocks: Why Corcept Therapeutics Stock Is Soaring
U.S. Patent Trial and Appeals Board Affirms Validity of All Claims of Corcept's U.S. Patent No.10,195,214
05:40pm, Wednesday, 18'th Nov 2020
MENLO PARK, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met
Corcept Therapeutics' (LAUR) CEO Eilif Serck-Hanssen on Q3 2020 Results - Earnings Call Transcript
02:14am, Sunday, 08'th Nov 2020
Corcept Therapeutics' (LAUR) CEO Eilif Serck-Hanssen on Q3 2020 Results - Earnings Call Transcript
Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2020 Results - Earnings Call Transcript
09:10am, Saturday, 07'th Nov 2020
Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2020 Results - Earnings Call Transcript
Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2020 Results - Quick Version Earnings Call Transcript
07:05pm, Tuesday, 03'rd Nov 2020
Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2020 Results - Quick Version Earnings Call Transcript
Corcept Therapeutics: Q3 Earnings Insights
04:29pm, Tuesday, 03'rd Nov 2020
Shares of Corcept Therapeutics (NASDAQ:CORT) fell 4.49% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 22.58% over the past year to $0.24, whi
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
04:05pm, Tuesday, 27'th Oct 2020
MENLO PARK, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on
Wall Street Breakfast: The Week Ahead
09:35am, Saturday, 05'th Sep 2020
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
Russell Investments Group Ltd. Boosts Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)
06:56am, Saturday, 22'nd Aug 2020
Russell Investments Group Ltd. grew its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 155.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchan
Strongbridge Biopharma's Recorlev Phase 3 Topline Data Due September 2020 Is A Major Value Inflection Point (NASDAQ:SBBP)
10:35pm, Monday, 10'th Aug 2020
Recorlev's Cushing's disease phase 3 topline data is due 9/2020. If the data looks good, NDA submission follows.
Shuman Glenn & Stecker Investigates Corcept Therapeutics, Inc.
09:56pm, Wednesday, 05'th Aug 2020
Shuman, Glenn & Stecker Investigates Corcept Therapeutics, Inc.
Corcept (CORT) Q2 Earnings Top Estimates, Revenues Miss Mark
06:11pm, Wednesday, 05'th Aug 2020
Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.
Corcept Therapeutics Incorporated (CORT) Q2 2020 Earnings Call Transcript
06:01am, Wednesday, 05'th Aug 2020
Today, we issued a press release announcing our financial results for the second quarter and providing a corporate update. It was $4.7 million lower than in the first quarter of this year, primarily
